Search research articles
Contact Us
Filters
Showing results (1-10 of 522) with videos related to
Page
of 53
Sort By:
Oncology (Williston Park, N.Y.)
|
October 22, 2021
COLOMATE challenge to overcome resistance in metastatic colorectal cancer
Takayuki Yoshino
Oncology (Williston Park, N.Y.)
|
September 22, 2021
The COLOMATE Platform: An Indispensable Initiative Promoting True Precision Oncology Prioritized for Patients With Cancer-From "MAYBE" to "MUST BE"
Takayuki Yoshino
Clinical Advances in Hematology & Oncology : H&O
|
April 12, 2021
Use of regorafenib before re-challenging with chemotherapy-based regimens in patients with metastatic colorectal cancer: mechanistic rationale
Takayuki Yoshino
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine
|
December 5, 2012
[109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 1. Recent treatments and progress in malignant tumors--chemotherapy and molecular targeting agents. Antibody therapy; 1) Update on the treatment for colorectal cancer]
Takayuki Yoshino
Clinical Advances in Hematology & Oncology : H&O
|
July 29, 2020
Current and Future Research Into the Mechanism of Action of Regorafenib
Takayuki Yoshino
Nihon Rinsho. Japanese Journal of Clinical Medicine
|
April 3, 2015
[Chemotherapeutic agents and electrolyte imbalance]
Yusuke Hashimoto, Takayuki Yoshino
Nihon Rinsho. Japanese Journal of Clinical Medicine
|
March 7, 2014
[Perspective of personalized (precise) cancer therapy based on predictive biomarkers]
Shozo Osera, Takayuki Yoshino
Nihon Rinsho. Japanese Journal of Clinical Medicine
|
December 15, 2018
Integration of clinical information and molecular biology profile -Endeavor of SCRUM-Japan-
Wataru Okamoto, Takayuki Yoshino
European Journal of Cancer (Oxford, England : 1990)
|
September 20, 2024
Response to letter re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness
Sebastian Stintzing, Takayuki Yoshino
The Oncologist
|
April 28, 2018
Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Yoshiaki Nakamura, Takayuki Yoshino
Page
of 53
Search research articles
Search
Showing results (1-10 of 522) with videos related to
Sort By:
Page
of 53
Oncology (Williston Park, N.Y.)
|
October 22, 2021
COLOMATE challenge to overcome resistance in metastatic colorectal cancer
Takayuki Yoshino
Oncology (Williston Park, N.Y.)
|
September 22, 2021
The COLOMATE Platform: An Indispensable Initiative Promoting True Precision Oncology Prioritized for Patients With Cancer-From "MAYBE" to "MUST BE"
Takayuki Yoshino
Clinical Advances in Hematology & Oncology : H&O
|
April 12, 2021
Use of regorafenib before re-challenging with chemotherapy-based regimens in patients with metastatic colorectal cancer: mechanistic rationale
Takayuki Yoshino
Nihon Naika Gakkai Zasshi. the Journal of the Japanese Society of Internal Medicine
|
December 5, 2012
[109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 1. Recent treatments and progress in malignant tumors--chemotherapy and molecular targeting agents. Antibody therapy; 1) Update on the treatment for colorectal cancer]
Takayuki Yoshino
Clinical Advances in Hematology & Oncology : H&O
|
July 29, 2020
Current and Future Research Into the Mechanism of Action of Regorafenib
Takayuki Yoshino
Nihon Rinsho. Japanese Journal of Clinical Medicine
|
April 3, 2015
[Chemotherapeutic agents and electrolyte imbalance]
Yusuke Hashimoto, Takayuki Yoshino
Nihon Rinsho. Japanese Journal of Clinical Medicine
|
March 7, 2014
[Perspective of personalized (precise) cancer therapy based on predictive biomarkers]
Shozo Osera, Takayuki Yoshino
Nihon Rinsho. Japanese Journal of Clinical Medicine
|
December 15, 2018
Integration of clinical information and molecular biology profile -Endeavor of SCRUM-Japan-
Wataru Okamoto, Takayuki Yoshino
European Journal of Cancer (Oxford, England : 1990)
|
September 20, 2024
Response to letter re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness
Sebastian Stintzing, Takayuki Yoshino
The Oncologist
|
April 28, 2018
Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer
Yoshiaki Nakamura, Takayuki Yoshino
Page
of 53